This is a snippet of the transcript, sign up to read more.
Most of these scientists are very good at their work and have started somewhere. For example, Merck Millipore was the company that trained many of them at the grassroots level. I'll give you an example, if you talk about sterile filtration, to most guys, it's 0.22 micron. If we ask ourselves how we got to that, it's basically that 0.45 was the original sterilizing filtration rate. Someone has said we need to halve that and Millipore said, that's not a 0.2 micron, it's a 0.22. They were the ones that got in at university levels, very quickly. They have these type one water systems and everyone calls it Milli-Q water. It comes down to what the scientists are used to and what they were comfortable with during their research. When they move to a bigger company, like Amgen, they would call the representative they knew from their research days. That's typically how the incumbent gets the business.
This is a snippet of the transcript, sign up to read more.
If I'm a Sartorius representative, I would tell the client that I have a reusable base column that is cost-effective for the development phase. The same technology can be offered in the same format later down the spectrum but in a single-use format. This makes the transition from reuse to single-use easier and shortens the time span of reprocessing. It also makes the process more scalable for larger volumes. Technology is crucial in this regard.
This is a snippet of the transcript, sign up to read more.
Price will always be a factor, but in reality, the product must be cost-effective and do the job. This is our way of thinking. Price isn't everything because cheap products often have a feeling of being cheap and cannot produce quality.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research